JERUSALEM, Israel , Sept. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be hosting a scientific webinar on Wednesday, September 18, 2024 , at 11 AM EDT / 18:00 Israel time.
The webinar will address the unmet needs in treating mild to moderate plaque psoriasis and explore intralesional injections of Scinai's novel anti-IL-17A/F VHH antibody as a promising solution. Additional topics will include an introduction to single domain VHH antibodies, Scinai's pipeline and a review of the biological drug development journey towards marketing authorization. The virtual panel discussion will feature: The webinar will be broadcast via Zoom.
Interested participants can register using the following LINK . The discussion will provide an in-depth exploration of the plaque psoriasis landscape, current treatment options, existing unmet needs, and the potential of intralesional injections of anti-IL-17A/F single domain VHH antibodies to offer a superior treatment for those affected. Topics will include: Participants will also have the opportunity to submit questions and receive answers during a Q&A session at the end of the webinar.
About Scinai Immunotherapeutics Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two comp.